| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.061 | 0.2 |